These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17426886)

  • 21. A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine.
    Valdés I; Izquierdo A; Cobas K; Thao P; Anh Duc H; Duc Loc H; Dung LT; Lazo L; Suzarte E; Pérez Y; Romero Y; Yaugel M; Marcos E; Guzmán MG; Dat DT; Hien ND; Guillén G; Gil L; Hermida L
    J Gen Virol; 2019 Jun; 100(6):975-984. PubMed ID: 31090533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
    Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
    Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.
    Raviprakash K; Wang D; Ewing D; Holman DH; Block K; Woraratanadharm J; Chen L; Hayes C; Dong JY; Porter K
    J Virol; 2008 Jul; 82(14):6927-34. PubMed ID: 18480438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.
    Pletnev AG; Swayne DE; Speicher J; Rumyantsev AA; Murphy BR
    Vaccine; 2006 Sep; 24(40-41):6392-404. PubMed ID: 16831498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
    Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
    Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.
    Eckels KH; Dubois DR; Putnak R; Vaughn DW; Innis BL; Henchal EA; Hoke CH
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):12-6. PubMed ID: 14740950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue-2 vaccine: viremia and immune responses in rhesus monkeys.
    Scott RM; Nisalak A; Eckels KH; Tingpalapong M; Harrison VR; Gould DJ; Chapple FE; Russell PK
    Infect Immun; 1980 Jan; 27(1):181-6. PubMed ID: 6766903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
    Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of recent and minimally passaged Brazilian dengue viruses inducing robust infection in rhesus macaques.
    Borges MB; Marchevsky RS; Mendes YS; Mendes LG; Duarte AC; Cruz M; de Filippis AMB; Vasconcelos PFC; Freire M; Homma A; Mossman S; Lepine E; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
    PLoS One; 2018; 13(4):e0196311. PubMed ID: 29694440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.
    Putnak R; Barvir DA; Burrous JM; Dubois DR; D'Andrea VM; Hoke CH; Sadoff JC; Eckels KH
    J Infect Dis; 1996 Dec; 174(6):1176-84. PubMed ID: 8940206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
    Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
    Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.
    Simmons M; Porter KR; Hayes CG; Vaughn DW; Putnak R
    J Virol; 2006 Oct; 80(19):9577-85. PubMed ID: 16973561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.
    Imoto J; Konishi E
    Vaccine; 2007 Jan; 25(6):1076-84. PubMed ID: 17084490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.
    McBurney SP; Sunshine JE; Gabriel S; Huynh JP; Sutton WF; Fuller DH; Haigwood NL; Messer WB
    Vaccine; 2016 Jun; 34(30):3500-7. PubMed ID: 27085173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
    Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
    Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.